Rafael Amado
2016 - Adaptimmune Therapeutics
In 2016, Rafael Amado earned a total compensation of $1.2M as Chief Medical Officer at Adaptimmune Therapeutics, a 57% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $116,100 |
|---|---|
| Option Awards | $674,104 |
| Salary | $430,000 |
| Other | $20,290 |
| Total | $1,240,494 |
Amado received $674.1K in option awards, accounting for 54% of the total pay in 2016.
Amado also received $116.1K in non-equity incentive plan, $430K in salary and $20.3K in other compensation.
Rankings
In 2016, Rafael Amado's compensation ranked 7,224th out of 14,075 executives tracked by ExecPay. In other words, Amado earned more than 48.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,224 out of 14,075 | 49th |
Division Manufacturing | 2,723 out of 5,489 | 50th |
Major group Chemicals And Allied Products | 892 out of 1,895 | 53rd |
Industry group Drugs | 692 out of 1,538 | 55th |
Industry Biological Products, Except Diagnostic Substances | 121 out of 279 | 57th |
Source: SEC filing on April 28, 2017.
Amado's colleagues
We found three more compensation records of executives who worked with Rafael Amado at Adaptimmune Therapeutics in 2016.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019